Literature DB >> 8641325

The effect of pH on the buccal and sublingual absorption of captopril.

J C McElnay1, T A al-Furaih, C M Hughes, M G Scott, J S Elborn, D P Nicholls.   

Abstract

The effect of pH on the buccal and sublingual absorption of captopril was evaluated using in vitro techniques and human studies. Partitioning of captopril into n-octanol was lowest over the pH range 5 to 8 and highest at pH values 3, 4 and 9. Using the buccal absorption technique, the partitioning of captopril (2 mg) was examined in six healthy male volunteers from buffered solutions (pH 3, 4, 5, 6, 7, 8, and 9). Lowest buccal partitioning occurred at pH 3 while maximal buccal partitioning occurred at pH 7. These data clearly indicated that the buccal absorption of captopril pharmacokinetic and pharmacodynamic parameters were determined after administration of buffered sublingual captopril (pH 7, optimal hP for absorption as determined from the buccal partitioning data) and unbuffered sublingual captopril. The study was performed in eight healthy volunteers in a randomised single-blind cross-over fashion. The tmax for captopril was found to be approximately 11 minutes earlier after buffered versus unbuffered sublingual administration and AUC0-30 min increased by approximately 30% in the case of buffered captopril. Cpmas, AUC0-180 min and relative bioavailability did not differ between the buffered and unbuffered administration. Pharmacodynamic parameters (BP, heart rate and plasma renin activity) did not differ significantly between buffered and unbuffered sublingual administration. The increased rate of captopril absorption after buffered sublingual administration was small and is likely to offer little therapeutic advantage over conventional sublingual formulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8641325     DOI: 10.1007/bf00194953

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Sublingual captopril--a pharmacokinetic and pharmacodynamic evaluation.

Authors:  T A al-Furaih; J C McElnay; J S Elborn; R Rusk; M G Scott; J McMahon; D P Nicholls
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Drug delivery via the mucous membranes of the oral cavity.

Authors:  D Harris; J R Robinson
Journal:  J Pharm Sci       Date:  1992-01       Impact factor: 3.534

3.  Correlation of partition coefficients in n-heptane-aqueous systems with buccal absorption data for a series of amines and acids.

Authors:  A H Beckett; A C Moffat
Journal:  J Pharm Pharmacol       Date:  1969-12       Impact factor: 3.765

4.  Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes.

Authors:  A H Beckett; E J Triggs
Journal:  J Pharm Pharmacol       Date:  1967-12       Impact factor: 3.765

5.  Simplified determination of captopril in plasma by high-performance liquid chromatography.

Authors:  C M Pereira; Y K Tam; R L Collins-Nakai; P Ng
Journal:  J Chromatogr       Date:  1988-03-04

6.  Analysis of captopril and hydrochlorothiazide combination tablet formulations by liquid chromatography.

Authors:  J Kirschbaum; S Perlman
Journal:  J Pharm Sci       Date:  1984-05       Impact factor: 3.534

7.  The use of buccal partitioning as a model to examine the effects of aluminium hydroxide gel on the absorption of propranolol.

Authors:  J C McElnay; D J Temple
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

8.  Determination of captopril in blood and urine by high-performance liquid chromatography.

Authors:  Y Kawahara; M Hisaoka; Y Yamazaki; A Inage; T Morioka
Journal:  Chem Pharm Bull (Tokyo)       Date:  1981-01       Impact factor: 1.645

9.  Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors.

Authors:  S A Ranadive; A X Chen; A T Serajuddin
Journal:  Pharm Res       Date:  1992-11       Impact factor: 4.200

10.  Stereospecific absorption and degradation of cephalexin.

Authors:  I Tamai; H Y Ling; S M Timbul; J Nishikido; A Tsuji
Journal:  J Pharm Pharmacol       Date:  1988-05       Impact factor: 3.765

View more
  4 in total

1.  A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure.

Authors:  J C McElnay; T A al-Furaih; C M Hughes; M G Scott; D P Nicholls
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

2.  Experimental and Molecular Modeling Studies on the Complexation of Chromium(III) with the Angiotensin-Converting Enzyme Inhibitor Captopril.

Authors:  Shimaa A Mahmoud; Mohamed Taha; Eman S H Khaled; Walid Hamdy Hassan; Fatma I Abo El-Ela; Ahmed A Abdel-Khalek; Reham A Mohamed
Journal:  ACS Omega       Date:  2022-04-28

Review 3.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Formulation and in vitro evaluation of a fast-disintegrating/sustained dual release bucoadhesive bilayer tablet of captopril for treatment of hypertension crises.

Authors:  Sahar Abbasi; Gholamhossein Yousefi; Ali Asghar Ansari; Soliman Mohammadi-Samani
Journal:  Res Pharm Sci       Date:  2016-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.